Ozmosi | Sodium chloride Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Sodium chloride

Alternative Names: sodium chloride, sodium-chloride, sodium chloride 0.9% in plastic container, sodio cloruro, natriumklorid, natriumchlorid, natrijev klorid, natrii chloridi infundibile, cloruro de sodio, cloreto de sodio, broncho saline, diluent, nacellate solution 0.9% - 500ml, nacellate solution 0.9% - 100ml, nacellate solution 0.9% - 250ml, hespan, nacellate solution 0.9% - 1000ml, corvatrol 0.9%, moviprep, plenvu, golytely, nulytely, balanced salt, tis-u-sol, procalamine, colyte with flavor packs, aminosyn ii 8.5% w/ electrolytes, colyte-flavored, glycoprep, go-evac, aminosyn 3.5% m in plastic container, isolyte s ph 7.4 in plastic container, lactated ringer's in plastic container, plasma-lyte 56 in plastic container, isolyte e in plastic container, prismasol bgk 4/0 in plastic container, ringer's in plastic container, prismasol b22gk 2/0 in plastic container, aminosyn 8.5% w/electrolytes, aminosyn ii 3.5% m in plastic container, isolyte s in plastic container, phoxillum b22k 4/0 in plastic container, prismasol bk 0/3.5 in plastic container, prismasol bgk 4/2.5 in plastic container, travasol 5.5% sulfite free w/ electrolytes in plastic container, plasma-lyte r in plastic container, prismasol bgk 4/3.5 in plastic container, travasol 3.5% sulfite free w/ electrolytes in plastic container, colyte, bss, physiolyte in plastic container, normosol-r in plastic container, e-z-em prep lyte, prismasol b22gk 4/2.5 in plastic container, tis-u-sol in plastic container, aminosyn 7% w/ electrolytes, aminosyn ii 7% w/ electrolytes, physiosol ph 7.4 in plastic container, plegisol in plastic container, multiple electrolytes injection type 1 usp ph 5.5, plasma-lyte 148 in water in plastic container, prismasol bgk 2/0 in plastic container, trilyte, nulytely-flavored, normocarb hf 35, aminosyn 3.5% m, aminosyn ii 10% w/ electrolytes, lax-lyte with flavor packs, prismasol bk 0/0/1.2 in plastic container, tpn electrolytes in plastic container, prismasol bk 0/0 in plastic container, prismasol b22gk 2/2.5 in plastic container, tham-e, travasol 3.5% w/ electrolytes, travasol 8.5% sulfite free w/ electrolytes in plastic container, clenz-lyte, peg-lyte, colovage, prismasol b22gk 4/0 in plastic container, aminosyn ii 3.5% m, freamine iii 3% w/ electrolytes, co-lav, acetated ringer's in plastic container, aminosyn 8.5% w/ electrolytes, aminosyn ii 8.5% w/electrolytes, travasol 8.5% w/ electrolytes, multiple electrolytes injection type 1 usp ph 7.4, bss plus, physiosol in plastic container, prismasol bgk 2/3.5 in plastic container, phoxillum bk 4/2.5 in plastic container, elliotts b solution, cardioplegic in plastic container, prismasol bk 4/2.5 in plastic container, travasol 5.5% w/ electrolytes, synovalyte in plastic container, ocl, plasma-lyte a in plastic container, prismasol bgk 4/0/1.2 in plastic container, navstel, prismasol bgk 0/2.5 in plastic container, normocarb hf 25, suclear
Clinical Status: Inactive
Latest Update: 2026-02-04
Latest Update Note: Clinical Trial Update

Product Description

Sodium chloride is an inorganic chloride salt having sodium(1+) as the counterion. It has a role as an emetic and a flame retardant. It is an inorganic chloride and an inorganic sodium salt. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Sodium-chloride)

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous, Intramuscular, Subcutaneous

FDA Designation: *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Norgine
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sodium chloride

Countries in Clinic: Australia, Austria, Belgium, Brazil, Bulgaria, Chile, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Kenya, Latvia, Lithuania, Malawi, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Russia, Slovenia, South Africa, South Korea, Spain, Sweden, Taiwan, Uganda, United Kingdom, United States, Unknown Location, Zimbabwe

Active Clinical Trial Count: 113

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Abscess|Asthma, Allergic|Ataxia Telangiectasia|Cervical Cancer|Cervical Intraepithelial Neoplasia|Communicable Diseases|Conjunctivitis, Allergic|Dust mite Hypersensitivity|Emphysema|Endometritis|Environmental Hypersensitivity|Esophageal Cancer|Fallopian Tube Diseases|HIV Infections|Heart Failure|Herpes Zoster|Inflammation|Influenza, Human|Injuries/wounds Unspecified|Kidney Diseases|Lyme Disease|Meningitis|Neuralgia, Postherpetic|Non-Small-Cell Lung Cancer|Oophoritis|Other|Ovarian Diseases|Papillomavirus Infections|Peritonitis|Pleural Effusion, Malignant|Pneumonia|Respiratory Syncytial Virus Infections|Respiratory Tract Infections|Rhinitis, Allergic|Salpingitis|Small Cell Lung Cancer|Small Fiber Neuropathy|Squamous Intraepithelial Lesions of the Cervix|Thyroid Eye Disease|Urinary Tract Infections|alpha 1-Antitrypsin Deficiency

Phase 2: Abdominal Pain|Acute Coronary Syndrome|Alzheimer Disease|Anesthesia Related|Atrial Fibrillation|Bronchopulmonary Dysplasia|Bunion|CADASIL|Cardiac Arrest|Chickenpox|Chronic Pain|Crohn Disease|Fatty Liver, Alcoholic|Glabellar Reflex|Gonorrhea|Hallux Valgus|Hepatitis E|Hypotension, Orthostatic|Ischemic Stroke|Keratoconjunctivitis Sicca|Low Back Pain|Malaria, Falciparum|Menopause|Neuromyelitis Optica|Non-alcoholic Fatty Liver Disease|Oncology Hematological Unspecified|Oncology Unspecified|Orthostatic Intolerance|Osteoarthritis, Knee|Pseudomonas Infections|Sexually Transmitted Diseases|Staphylococcal Infections|Surgical Wound Infection|Total Knee Arthroplasty|beta-Thalassemia

Phase 1: Acute Pain|Adenoviridae Infections|Angina Pectoris|Appendicitis|Arthritis, Infectious|Arthritis, Rheumatoid|Bacteroides Infections|Bronchiectasis|COVID-19|Clostridium Infections|Conjunctivitis|Coronary Disease|Fusobacterium Infections|Gram-Positive Bacterial Infections|Healthy Volunteers|Hypertension|Hypertriglyceridemia|Idiopathic Pulmonary Fibrosis|Keratitis|Myocardial Infarction|Pelvic Infection|Pelvic Inflammatory Disease|Pneumococcal Infections|Pyelonephritis|Type 2 Diabetes

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2023-506031-15-01

SRB2021260

P2

Recruiting

Cardiac Arrest

2030-11-30

2025-05-02

Treatments

2022-500293-34-01

EVENEW

P2

Recruiting

Bronchopulmonary Dysplasia

2028-06-30

2025-05-02

Treatments

2025-522558-37-00

2025-522558-37-00

P2

Not yet recruiting

Menopause

2028-05-31

NCT07077746

HBCD01

P2

Recruiting

Crohn Disease

2027-12-01

12%

2025-09-10

Primary Endpoints

NCT05952804

RG1123550

P2

Recruiting

Oncology Unspecified|Oncology Hematological Unspecified

2027-07-31

83%

2025-04-24

Primary Endpoints|Treatments

2024-519366-52-00

IP-001-24

P2

Not yet recruiting

Kidney Diseases

2027-06-01

2024-514903-33-00

2024-514903-33-00

P2

Active, not recruiting

Total Knee Arthroplasty|Osteoarthritis, Knee

2027-06-01

2025-05-02

Treatments

2023-509261-20-00

MOZEG

P2

Not yet recruiting

Ischemic Stroke

2027-03-03

2025-05-02

Treatments

NCT06606561

NVL-2024-257

P2

Not yet recruiting

Osteoarthritis, Knee

2026-04-01

50%

2025-06-06

Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments

2024-513828-42-00

2024-513828-42-00

P2

Recruiting

CADASIL

2026-03-31

2025-05-02

Treatments

NCT06188663

STOOD

P2

Recruiting

Orthostatic Intolerance|Hypotension, Orthostatic

2026-03-01

2024-07-05

2025-521522-15-00

APISLIT-DD-D-2025-01

P2

Not yet recruiting

Rhinitis, Allergic|Environmental Hypersensitivity|Dust mite Hypersensitivity|Conjunctivitis, Allergic

2026-02-02

2023-507249-27-00

FTP-CLIN-01

P2

Recruiting

Glabellar Reflex

2026-01-27

2025-05-02

Treatments

CTR20243840

CTR20243840

P2

Completed

Anesthesia Related

2026-01-05

2026-02-01

Primary Completion Date|Study Completion Date|Treatments|Trial Status

NCT06306196

IVI Hecolin S001

P2

Not yet recruiting

Hepatitis E

2026-01-01

2024-03-13

Primary Endpoints|Treatments

NCT06319235

DUO2022_01

P2

Recruiting

Pseudomonas Infections|Staphylococcal Infections|Communicable Diseases|Surgical Wound Infection

2025-12-31

12%

2024-03-20

Primary Endpoints|Treatments

2023-506589-30-00

VAC52416BAC3001

P3

Active, not recruiting

Urinary Tract Infections

2029-06-30

60%

2025-05-02

Treatments

2022-501717-31-00

2022-501717-31-00

P3

Not yet recruiting

Small Fiber Neuropathy

2027-12-31

2025-05-02

Treatments

2024-512658-41-00

CQ-001-19

P3

Recruiting

Heart Failure

2027-04-01

2025-05-02

Treatments

2023-509137-39-00

MK-3475-091

P3

Active, not recruiting

Small Cell Lung Cancer|Non-Small-Cell Lung Cancer

2027-02-02

2025-05-02

Treatments

2025-522046-42-00

NER1006-01/2025

P3

Not yet recruiting

Other

2027-01-06

10%

2023-504942-75-01

PM/0059

P3

Active, not recruiting

Asthma, Allergic|Rhinitis, Allergic|Environmental Hypersensitivity|Dust mite Hypersensitivity|Conjunctivitis, Allergic

2026-08-31

2025-05-02

Treatments

2023-510030-83-00

GTi1201

P3

Active, not recruiting

alpha 1-Antitrypsin Deficiency|Emphysema

2026-08-12

2025-05-02

Treatments

2024-512388-29-00

FGTW2101

P3

Recruiting

Injuries/wounds Unspecified

2026-04-30

2025-05-02

Treatments

2023-509105-72-00

C4601003

P3

Active, not recruiting

Lyme Disease

2025-12-31

59%

2025-05-02

Treatments